MoCA’s (Mechanism of Coordinated Access to Orphan Medicinal Products) state of play

Ana Palma
2nd Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies
Brussels, 22 February 2017
Disclaimer & Acknowledgements

- The materials developed for this presentation have been done in very close collaboration with Dr. Anna Bucsics, Advisor to MEDEV and the MoCA Project

- The input from Dr. Anna Bucsics is gratefully acknowledged
• P&R authorities often lack sufficient, robust and trusted information on which to base their decisions
• Uncertainty increases in fields of high innovation and in limited or small populations, e.g., Orphan Medicinal Products
• Delays and inequalities in access to patients

Challenges are shared – across borders and between stakeholders

=> Shared objective: healthcare systems committed to treat patients in a timely, equitable and sustainable way

Solutions can be better explored collaboratively, rather than unilaterally

Courtesy from Wills Hughes-Wilson, Sobi
MoCA – addressing the last cornerstone: The Payers

MoCA is a
- voluntary
- non-legislative,
- non-regulatory and
- non-binding collaboration

Among stakeholders* who are willing to work together to provide real access to a real solution for real patients with real unmet medical needs

* Patients: EURORDIS and individual patients or patients’ organisations relevant to a specific Orphan Medicine on an ad-hoc basis

* Payers: 13 Volunteer National competent authorities for P&R, members of MEDEV (Medicines Evaluation Committee)

* Pharmaceutical Industry: candidate MAA / MAH (mostly SME’s, including start-ups)

Courtesy from Anna Bucsics, MEDEV & MoCA
How does MoCA work?

- Expression of interest by a company
- Initial presentation at a MoCA meeting
- **Dialogue** continues in a consensually established way
- Final report containing learnings and recommendations. These may concern:
  - Patient numbers and estimates of use
  - Product delivery/treatment centers
  - Registries
  - Ultimately, a framework for negotiations (eg Transparent Value Framework)

- Confidential and non-binding (unless otherwise agreed)
- „Opt-out“ anytime; currently free of charge for companies
Experience to date

### Overall:

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of Participating Companies</td>
<td>10</td>
</tr>
<tr>
<td>No of Products Discussed</td>
<td>13</td>
</tr>
<tr>
<td>Small Molecules</td>
<td>4</td>
</tr>
<tr>
<td>Biologicals</td>
<td>3</td>
</tr>
<tr>
<td>Advanced Therapies</td>
<td>4</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
</tr>
</tbody>
</table>

### Product status @ 1\textsuperscript{st} dialogue:

<table>
<thead>
<tr>
<th>Status</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorised</td>
<td>2</td>
</tr>
<tr>
<td>MA submitted</td>
<td>2</td>
</tr>
<tr>
<td>Post phase 2/Phase 3</td>
<td>4</td>
</tr>
<tr>
<td>Phase 1/2</td>
<td>4</td>
</tr>
<tr>
<td>Pre-clinical</td>
<td>1</td>
</tr>
</tbody>
</table>

Courtesy from Anna Bucsics, MEDEV & MoCA
Learnings from MoCA

For Patients:
• Opportunity to inform other stakeholders of patients’ priorities and needs
• Understanding of payers’ concerns – and their reasons

For Industry:
• Better understanding of which outcomes matter to patients and payers
• Companies are welcome anytime during the product cycle – but the earlier the better

For Payers:
• „Heads-up“ for earlier planning
• Opportunity to influence trial design so that payers’ information needs can be considered

Understanding the challenges of complex technologies, for complex rare diseases, which are complex to treat

Building trust

Courtesy from Anna Bucsics, MEDEV & MoCA
MoCA = Multi-stakeholder collaboration

What can be improved:

- No “single payer voice”: great heterogeneity across and within countries
- Legal issue / political issue / organisational issue: not all payers have the same mandate
- Concerns about independency: early involvement
- Payers to come at early dialogues table with regulators and HTAs: no consensus
- Greater collaboration needed not only among stakeholders, but also among payers (multi-country)
- More trust → more dialogue
MoCA & other initiatives

Collaboration
Address Early Sustainable Access
Thank you for your attention!

ana.palma@sobi.com